George K. Aghajanian (April 14, 1932 – July 4, 2023) was an American psychiatrist who was
Emeritus Foundations Fund Professor at the
Yale School of Medicine,[1]New Haven, Connecticut, in the Department of Psychiatry. He was a pioneer in the area of
neuropharmacology. He also served as a member of the
NARSAD Scientific Advisory Board.[2]
Aghajanian was a medical officer in the
United States Army in the starting days of his career.[3] He served different positions at the Yale School of Medicine, including assistant professor of psychiatry, professor of psychiatry and pharmacology, and Foundations Fund professor of research in psychiatry.[1]
George Aghajanian died on July 4, 2023, at the age of 91.[4]
George K Aghajanian: Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology.[16]
George Aghajanian, Benjamin S Bunney, and Philip S Holzman: Patricia Goldman-Rakic, 1937–2003. Neuropsychopharmacology.[17]
George K Aghajanian and Gerard J Marek: Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews.[18]
George K Aghajanian and Gerard J Marek: Serotonin–Glutamate Interactions: A New Target for Antipsychotic Drugs. Neuropsychopharmacology.[19]
George K.Aghajanian and Gerard J Marek: Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Research.[20]
Ronald S Duman, George K Aghajanian, Gerard Sanacora, and John H Krystal: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine.[21]
Ronald S Duman and George K Aghajanian: Neurobiology of Rapid Acting Antidepressants: Role of BDNF and GSK-3β. Neuropsychopharmacology.[22]
Ronald S. Duman and George K. Aghajanian: Synaptic Dysfunction in Depression: Potential Therapeutic Targets. Science.[23]